Moleculin Biotech (MBRX) Projected to Post Earnings on Tuesday

Moleculin Biotech (NASDAQ:MBRX) is projected to announce its Q2 2026 results before the market opens on Tuesday, August 11th. Analysts expect the company to announce earnings of ($1.6050) per share for the quarter. Investors may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 4:00 PM ET.

Moleculin Biotech (NASDAQ:MBRX) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($3.54) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.33) by ($1.21). On average, analysts expect Moleculin Biotech to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Moleculin Biotech Stock Down 3.1%

Shares of NASDAQ MBRX traded down $0.01 during mid-day trading on Tuesday, reaching $0.41. 1,736,190 shares of the company were exchanged, compared to its average volume of 520,607. The stock has a market cap of $2.20 million, a price-to-earnings ratio of -0.02 and a beta of 1.84. Moleculin Biotech has a 1 year low of $0.16 and a 1 year high of $18.25. The firm has a 50-day moving average of $2.41 and a 200 day moving average of $2.73.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on MBRX. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Friday, July 17th. Wall Street Zen lowered shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research note on Saturday, May 16th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Moleculin Biotech presently has an average rating of “Hold” and an average price target of $22.00.

Institutional Investors Weigh In On Moleculin Biotech

An institutional investor recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new stake in Moleculin Biotech, Inc. (NASDAQ:MBRX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned about 1.11% of Moleculin Biotech as of its most recent SEC filing. 15.52% of the stock is currently owned by institutional investors.

Moleculin Biotech Company Profile

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.